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Background: Stage IV non–small-cell lung cancer (NSCLC) 
patients with oligometastases (< 5 metastatic lesions) may experi-
ence long-term survival when all macroscopic tumor sites are treated 
radically, but no prospective data on NSCLCs with synchronous 
oligometastases are available.
Methods: A prospective single-arm phase II trial was conducted. 
The main inclusion criteria were pathologically proven NSCLC stage 
IV with less than five metastases at primary diagnosis, amendable for 
radical local treatment (surgery or radiotherapy). The study is listed 
in clinicaltrials.gov, number NCT01282450.
Results: Forty patients were enrolled, 39 of whom were evaluable (18 
men, 21 women); mean age was 62.1 ± 9.2 years (range, 44–81). Twenty-
nine (74%) had local stage III; 17 (44%) brain, seven (18%) bone, and 
four (10%) adrenal gland metastases. Thirty-five (87%) had a single 
metastatic lesion. Thirty-seven (95%) of the patients received chemo-
therapy as part of their primary treatment. Median overall survival (OS) 
was 13.5 months (95% confidence interval 7.6–19.4); 1-, 2-, and 3-year 
OS was 56.4%, 23.3%, and 17.5%, respectively. Median progression-
free survival (PFS) was 12.1 months (95% confidence interval 9.6–14.3); 
1-year PFS was 51.3%, and both 2- and 3-year PFS was 13.6%. Only 
two patients (5%) had a local recurrence. No patient or tumor parameter, 
including volume and 18F-deoxyglucose uptake was significantly corre-
lated with OS or PFS. The treatment was well tolerated.
Conclusion: In this phase II study, long-term PFS was found in a 
subgroup of NSCLC patients with synchronous oligometastases 
when treated radically. Identification of this favorable subgroup 
before therapy is needed.
Key Words: Non–small-cell lung cancer, Oligometastases, 
Radiotherapy, Chemotherapy, stage IV, Combined modality treat-
ment, Individualized.
(J Thorac Oncol. 2012;7: 1547–1555)
Non–small-cell lung cancer (NSCLC) continues to be the leading cause of cancer deaths.1 At diagnosis, approxi-
mately 50% of the patients have already overt disseminated 
cancer. These stage IV patients are generally considered to be 
incurable and are mostly treated palliatively. However, a transi-
tion between macroscopic local disease and multiple metasta-
ses (polymetastases) has been proposed and is referred to as 
oligometastases, being a limited number of metastases (usually 
<5), which also should be amenable for radical local therapy.2–5 
The hypothesis is that patients with less than five distant metas-
tases may be curable when all detectable disease can be treated 
radically with a local modality, that is, surgery or radiotherapy.
The widespread introduction of stereotactic radio therapy 
(stereotactic body radiotherapy [SBRT] or stereotactic ablative 
radiotherapy [SABR]) and of minimally invasive sur gery has 
fuelled research in treating patients with oligometastases.6–23 
Indeed, local control of metastases can be obtained in 
virtually all parts of the body with a low proportion of 
patients experiencing severe side effects. However, only a few 
prospective studies have been published.9–11,13,15 In these series, 
patients with several cancer sites have been included and both 
synchronous and metachronous metastases were studied. It is 
therefore not possible to separate the outcome of NSCLC from 
that of other tumors and to exclude the selection bias of the 
time distant metastases occur, although in retrospective series, 
subgroups of stage IV NSCLC patients may fare better than 
some stage III patients.16 In the absence of prospective data 
in NSCLC with synchronous oligometastases, we launched a 
single-arm prospective phase II trial to investigate whether it 
would be possible to obtain a significant 2- and 3-year survival 
in these patients when treated radically.
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PATIENTS AND METHODS
Eligibility Criteria
Inclusion criteria were: histologically or cytologically 
proven NSCLC, Union International Centre le Cancer (UICC) 
stage IV (6th edition)24 with less than five metastases at the 
time of diagnosis. All tumor sites (local, regional, and distant) 
had to be amenable for radical treatment (surgery or radiother-
apy to a biological dose25 of at least 60 Gy in 30 daily fractions 
of 2 Gy, except for brain metastases in which lower radiation 
doses were allowed) according to the multidisciplinary team. 
Both surgery and radiotherapy were allowed in the same 
patient (e.g., radiotherapy as local treatment for the local 
N3-IIIB disease and surgery for a solitary adrenal metastasis). 
Systemic treatment was not mandatory. There were no size 
limitations to the primary tumor or its metastases. Intracranial 
metastases alone were allowed. Patients had to have a World 
Health Organization (WHO) performance status 0 to 2 and 
any other malignancy should be controlled, that is, in clinical 
complete remission, at the time of diagnosis. The exclusion 
criteria were: not NSCLC or mixed NSCLC and other histolo-
gies (e.g., small-cell carcinoma), and a T4 tumor because of a 
malignant pleural or pericardial effusion.
Endpoints
The primary endpoint was overall survival (OS) at 2 and 
3 years. The secondary endpoints were, progression-free sur-
vival (PFS), dyspnea, dysphagia, and patterns of recurrence.
Staging
Patients were staged with a calibrated26 whole-body 18F- 
deoxyglucose positron emission tomography computed 
tomography (CT) scan and a CT with intravenous contrast or 
a contrast-enhanced magnetic resonance imaging of the brain. 
Pathological confirmation of at least one distant metastasis 
was mandatory; for brain metastases, this was done only when 
the multidisciplinary team considered this diagnosis as most 
likely.
Comorbidity
Comorbidity at the time of diagnosis was scored using 
the Charlson comorbidity index.27
Treatment
Treatment of the primary tumor and the hilar and medi-
astinal lymph nodes. Loco-regional treatment was previously 
described and included image and dose-quality control.28,29 
Patients with local stage T1-3 N0-1 disease were offered a 
lobectomy and a lobe-specific nodal dissection, stereotactic 
body radiation therapy (SBRT) or more fractionated radio-
therapy for central lesions. Patients with local stage III (T4 
and/or N2-3) NSCLC received either sequential of concurrent 
individualized iso-toxic chemoradiotherapy.28,29
Radiotherapy dose was specified according to International 
Commission on Radiation Units and Measurements (ICRU) 
50 guidelines30 and European Organization for Research and 
Treatment of Cancer recommendations were used.31
Treatment of distant metastases. Patients with brain 
metastases were either treated with resection followed by 
whole-brain radiotherapy to a dose of 30 Gy in 10 daily frac-
tions of 3 Gy, or with stereotactic radiosurgery (SRS) to a 
dose of 18 to 20 Gy per one fraction or 24 Gy per three frac-
tions, depending on the volume and the location of the brain 
metastase(s).32 No prophylactic whole-brain irradiation was 
given after SRS.
When surgery was considered in case of extracranial 
metastases, a radical resection was envisaged. In case of a 
microscopic incomplete resection, postoperative radiotherapy 
was given to a dose of 60 Gy in 30 fractions in 6 weeks to the 
areas at risk.
The timing and sequencing treatment (e.g., first radio-
therapy, then surgery…) was not specified in the protocol and 
left to the discretion of the multidisciplinary group. Systemic 
treatment was not mandatory, but was considered to be the 
standard in stage IV patients. When a recurrence developed, 
the treatment was left at the discretion of the physician.
Post-treatment follow-up. The follow-up after all ther-
apy consisted of a visit after 3 weeks and thereafter every 3 
months, comprising history taking and physical examination; 
these were performed by the pulmonologist and radiation 
oncologist for the first 2 years. After this period, visits were 
performed every 6 months until 5 years post-treatment. A CT 
scan of the thorax and the upper abdomen and of the treated 
metastatic site was performed 3 and 6 months after comple-
tion of treatment and every 6 months thereafter. In case of 
brain metastases, a contrast-enhanced magnetic resonance 
imaging scan of the brain was done every 3 months. At the 
time of first recurrence, additional diagnostic imaging proce-
dures was left at the decision of the physician, as indicated 
by the presence of symptoms. A pathological confirmation of 
recurrence was not required.
Local tumor control of all radical treated locations (both 
the primary tumor and the metastases) was evaluated accord-
ing to the criteria of Green33 after radiotherapy and according 
to Response Evaluation Criteria In Solid Tumors for nonir-
radiated sites.34 Tumor progression was scored when one or 
both occurred.
Toxicity was scored according to the Common Toxicity 
Criteria for Adverse Events (CTCAE) 3.0 criteria (http://ctep.
cancer.gov) before the start of therapy, at the weekly visits dur-
ing treatment, and at the follow-up visits mentioned above by 
the physician and by the patient, the latter from 2009 onward.
Statistics. We hypothesized that the 2-year survival with 
this radical therapy should be at least 20% with a one-sided 
95% confidence interval (CI) not including 10% being the 
benchmark of 2-year survival with chemotherapy only.35 A 
sample size of 40 patients would be sufficient for this purpose.
Results are either expressed as mean ± SD with the 
range within parentheses or as a proportion with 95% CI. OS 
and PFS rates were calculated with the Kaplan–Meier method, 
on an intention-to-treat basis, starting from the date of diag-
nosis. OS and PFS comparisons were done using a log-rank 
test, and for multiple variables a Cox regression analysis was 
performed using SPSS 17.0.
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Ethics. The trial was approved by the required authori-
ties and all patients gave informed consent. The study is listed 
in clinicaltrials.gov, number NCT01282450.
RESULTS
Patients
Forty patients were included from July 27, 2006 until 
July 23, 2010, with one patient being ineligible. Analysis was 
performed on December 5, 2011. One patient was excluded 
from the analysis because of a protocol violation (61-year-
old man with a small-cell lung cancer stage T1N3M1, with a 
solitary symptomatic brain metastasis, treated with resection, 
followed by whole-brain irradiation therapy (WBRT) and con-
current cisplatin-etoposide and chest radiotherapy to a dose 
of 70 Gy. He is free of disease progression at 2 years). Patient 
and tumor characteristics are depicted in Table 1.
A biopsy of the primary tumor was available in 18 of 
39 patients (46%); in the remaining patients, only cytologi-
cal material was obtained. As determination of the epider-
mal growth factor receptor (EGFR) mutation status was not 
required and was not standard of care when the study began; 
this was only obtained in patients in patients with recurrent 
adenocarcinoma and only at the time when erlotinib became 
available. The EGFR mutation status was determined in three 
of 39 patients. In one of these, an exon 21 mutation was found 
and the patient was treated with erlotinib at relapse. Local 
stage (thus ignoring the M1 status) was I or II in 10 of 39 
patients, stage IIIA in nine (23.1%), and IIIB in 20 (51.3%).
The brain was the most frequent location of metastases 
(17 of 39 patients or 43.9%), followed by the bone (7 of 39, 
17.9%), and adrenal gland (4 of 39, 10.3%). The overwhelm-
ing majority of patients were diagnosed with a single distant 
metastasis (34 of 39, 87.2%).
For the whole patient group, the mean volumes were: 
primary tumor: 92.3 ± 122.7 cm3 (0–583.5) (median 51.9 cm3), 
lymph nodes: 44.2 ± 57.9 cm3 (0–238.8) (median 23.5 cm3), 
distant metastasis: 20.2 ± 27.4 cm3 (0.3–113.1) (median 
9.9 cm3), total tumor volume 144.3 ± 138.9 cm3 (9.5–696.5) 
(median 117.9 cm3).
The mean maximal standardized uptake value 
(SUVmax) of the primary tumor was 11.9 ± 5.7 (2.1–27) 
(median 10.2). Excluding brain metastases because of high 
physiological cerebral 18F-deoxyglucose uptake, the mean 
SUVmax of metastases was 6.7 ± 3.3 (2.3–14.4) (median 5.8).
Treatment
The primary tumor and its regional lymph nodes were 
treated with radiotherapy or chemoradiation, none with sur-
gery (Table 2). One primary tumor was treated with SBRT 
to a dose of 54 Gy in three fractions. Only two patients did 
not receive chemotherapy, one with stage T3N0 with one rib 
metastasis and one 82-old-man with a T2N2 tumor with a 
metastasis in the left major teres muscle. These two patients 
had a distant recurrence.
Three of the four patients with adrenal metastases were 
treated with surgery, and one was treated with radiotherapy 
TABLE 1. Patient and Tumor Characteristics (n = 39)
Age (yrs) (mean ± SD) (range) 62.1 ± 9.2 (44–81)
Sex
 Male 18 (46.2%)
 Female 21 (53.8%)
Comorbidity (modified Charlson)
 None 18 (46.2%)
 1 20 (51.3%)
 2 1 (2.6%)
WHO performance status
 0 12 (30.8%)
 1 26 (66.7%)
 2 1 (2.6%)
Pathology
 Adenocarcinoma 13 (33.3%)
 Large cell carcinoma 7 (17.9%)
 Large cell neuro-endocrine carcinoma 1 (2.6%)
 Non–small-cell lung cancer (NOS) 8 (20.5%)
 Undifferentiated carcinoma 2 (5.2%)
 Squamous cell carcinoma 8 (20.5%)
 T-stage
 T0 2 (5.1%)
 T1 5 (12.8%)
 T2 14 (35.9%)
 T3 8 (20.5%)
 T4 10 (25.6%)
N-stage
 N0 12 (30.8%)
 N1 4 (10.3%)
 N2 12 (30.8%)
 N3 11 (28.2%)
Local stage (ignoring M1 status)
 I 4 (10.3%)
 II 6 (15.4%)
 IIIA 9 (23.1%)
 IIIB 20 (51.3%)
Localization metastasis
 Adrenal gland 4 (10.3%)
 Bone 7 (17.9%)
 Brain 17 (43.9%)
 Gastro-hepatic ligament 1 (2.6%)
 Liver 1 (2.6%)
 Lung 1 (2.6%)
 Lymph node 2 (5.1%)
 Muscle 2 (5.1%)
 Ovary 1 (2.6%)
 Pleura 3 (7.7%)
Number metastases
 1 34 (87.2%)
 2 4 (10.3%)
 3 1 (2.6%)
WHO, World Health Organization; NOS, Not otherwise specified.
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because of irresectability (Table 3). All patients with bone 
metastases were treated with radiotherapy (54 Gy in 30 twice-
daily fractions of 1.8 Gy). Four of 17 patients with brain 
metastases were surgically treated, and the rest were treated 
with SRS. Resection was performed in the patients with a 
solitary liver, a contralateral lung, and an ovarian metastasis.
Survival
With a median follow-up of 27.7 ± 10.5 months (mean 
28.3 months; minimum 16.7 months, maximum 46.1 months), 
the median OS was 13.5 months (95% CI 7.6–19.4) (Fig. 1). 
The 1-year OS was 56.4%, the 2-year 23.3%, and the 3-year 
17.5%.
The median PFS was 12.1 months (95% CI 9.6–14.3) 
(Fig. 2). The 1-year PFS was 51.3%, both the 2- and 3-year 
PFS 13.6%. When split-up according to the location of the 
metastases, the median survival for adrenal locations was 10.2 
months, for bone 13.5 months, for brain 13.6 months, and for 
muscle 5.5 months (p = 0.52).
Patterns of Recurrence 
At the time of analysis, 6 patients (15.4%) of patients 
did not show a recurrence (Table 4). Of the 33 patients with a 
recurrence, 31 (79.5%) had the recurrence outside the radio-
therapy field (= planning target volume) or the surgical bed 
and two (5.1%) in-field (primary lung tumor in a T3N3M1 
NSCLC and mediastinal lymph nodes (T2N3M1).
Toxicity
Determined by the physician. The incidence of acute 
grade 3 oesophagitis was 15%, with only one patient still 
having grade 1 oesophagitis 3 months post-treatment. Three 
months after therapy, only three of /39 patients had grade 2 
dyspnea (compared with 2 of 39 at baseline).
Grade 3 cough only occurred in one patient, but 3 
months after therapy, no patient had cough of grade 2 or more 
(Table 5). After brain surgery, SRS, or other treatment of dis-
tant metastases, no toxicity of grade 3 or more was observed. 
One patient showed paresis grade 2, one seizures grade 2, two 
sensory neuropathy grade 2, two dizziness grade 1, and two 
headache grade 2. No side effects of grade 2 or more remained 
2 months post-treatment.
Determined by the patient. Twenty-three percent 
reported transient grade 3 esophagitis with no severe esopha-
gitis 3 months after therapy (Table 6). No grade 3 dyspnea 
or cough occurred. Three months after EGFR, 31% of the 
TABLE 2. Treatment for Primary Tumor and Lymph Nodes 
(n = 39)
Surgery 0
Radiotherapy alone 2 (5.1%)
Sequential chemoradiotherapy 15 (38.5%)
 Cisplatin-gemcitabine 11
 Carboplatin-gemcitabine 1
 Cisplatin-pemetrexed 3
Concurrent chemoradiotherapy 21 (53.8%)
 Cisplatin-etoposide 7
 Cisplatin-vinorelbine 14
 Adjuvant after radiotherapy 1 (2.6%)
 Cisplatin-gemcitabine —
Radiotherapy dose 62.3 ± 10.1 Gy (18–79.2)
Number of fractions 35.9 ± 8.4 3–44
Overall treatment time of 
radiotherapy
30.56 ± 10.3 days 3–44
TABLE 3. Radical Treatment of Metastases
Metastasis Location at Diagnosis
Radical Local  
Therapy of Metastases
Single metastasis
 Solitary adrenal Resection
 Solitary adrenal Resection
 Solitary adrenal Resection
 Solitary adrenal Radiotherapy
 Solitary bone Radiotherapy
 Solitary bone Radiotherapy
 Solitary bone Radiotherapy
 Solitary bone Radiotherapy
 Solitary bone Radiotherapy
 Solitary bone Radiotherapy
 Solitary brain Resection
 Solitary brain SRS
 Solitary brain SRS
 Solitary brain SRS
 Solitary brain Resection
 Solitary brain SRS
 Solitary brain Resection
 Solitary brain SRS
 Solitary brain SRS
 Solitary brain SRS
 Solitary brain Radiotherapy
 Solitary brain SRS
 Solitary brain Radiotherapy
 Solitary brain Resection
 Solitary heterolateral lung Resection
 Solitary left teres major muscle Radiotherapy
 Solitary lymph node ipsilateral axilla Radiotherapy
 Solitary lymph node left iliaca externa Radiotherapy
 Solitary ovary Resection
 Solitary pleura Radiotherapy
 Solitary pleura Radiotherapy
 Solitary pleura Radiotherapy
Multiple metastases
 Two brain metastases SRS
 Three brain metastases SRS
 Three brain metastases SRS
 One in the left pectoral muscle and one in the  
 right lung
Radiotherapy
 Two bone metastases (right ilium, right pubis) Radiotherapy
SRS, stereotactic radiosurgery.
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patients reported having a better health status as opposed to 
baseline and 15% reported a worse health status. The propor-
tion having a deterioration of health status after six months 
was 31%, correlating with cancer recurrence. There were no 
changes in mobility, self-care, activities of daily living, or 
mood over time.
Second-line treatment after recurrence. After a 
recurrence was diagnosed, nine patients (27.3%) only 
received best supportive care, mainly because of a bad general 
condition, seven (21.2%) were treated with chemotherapy 
only, and the rest received different treatments (Table 7).
Variables associated with OS and PFS. The follow-
ing parameters were analyzed: volume of the primary tumor, 
volume of the nodes, volume of the metastases, total tumor 
volume, SUVmax of the primary tumor and of the nonbrain 
metastases, local stage, WHO performance status, comor-
bidity score, location of metastases, number of metastases, 
histological type, sex, age, and sequential versus concurrent 
chemoradiotherapy. None of these variables showed a correla-
tion with OS or PFS, although a trend was noticed for the vol-
ume of the metastasis and OS (Table 8). The characteristics of 
the patients showing no disease progression are summarized 
in Table 9.
FIGURE 1. Overall survival (n = 39).
FIGURE 2. Progression-free survival.
TABLE 4. Patterns of Recurrence
Metastasis Location at Diagnosis Site of First Progression
Adrenal Peritoneum
Adrenal In-field mediastinal lymph nodes
Adrenal Bone
Adrenal No recurrence
Bone Bone
Bone Bone
Bone No recurrence
Bone No recurrence
Bone Bone
Bone Bone
Bone Bone
Brain Bone
Brain Brain
Brain Bone
Brain Bone
Brain Bone
Brain Brain
Brain No recurrence
Brain Brain
Brain Brain
Brain Brain
Brain Leptomeningeal
Brain Brain
Brain Brain
Brain Brain
Brain Brain
Brain Ovary
Brain Brain
Brain Bone
Node In-field primary tumor
Node Brain
Liver Liver
Gastro-hepatic ligament Brain
Lung No recurrence
Ovary Brain
Pleura No recurrence
Pleura Brain
Muscle Brain
Muscle Muscle, liver
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DISCUSSION
Patients with distant metastases of NSCLC were 
deemed incurable and classified as having stage IV disease.24 
The observation that individuals with solitary lung or liver 
metastases may show long-term disease-free survival and 
even cure provided support for the concept of oligometasta-
ses2,3,21,22 Patients with one to five distant metastases may be at 
a continuum between truly local disease and widely dissemi-
nated cancer. Radical local therapy may thus be able to cure a 
subset of these patients.
Data on patients with NSCLC are scarce. Most series 
are retrospective and the few prospective trials include syn-
chronous and metachronous metastases that are amendable 
for SBRT or limited surgery.13–15,23 Nevertheless, long-term 
survival was also observed in NSCLC.13–16,23
TABLE 5.  Toxicity Scored by the Physician
Dysphagia
 Baseline
  G0 39 (100%)
 Maximal
  G0 10 (25.6%)
  G1 16 (41%)
  G2 7 (17.9%)
  G3 6 (15.4%)
 3 mos post-treatment
  G0 38 (97.4%)
  G1 1 (2.6%)
Dyspnea
 Baseline
  G0 27 (69.2%)
  G1 10 (25.6%)
  G2 2 (5.1%)
 Maximal
  G0 21 (53.8%)
  G1 13 (33.3%)
  G2 5 (12.8%)
 3 mos post-treatment
  G0 24 (61.5%)
  G1 12 (30.8%)
  G2 3 (7.7%)
Cough
 Baseline
  G0 18 (46.2%)
  G1 20 (51.3%)
  G2 1 (2.6%)
 Maximal
  G0 10 (25.6%)
  G1 25 (64.1%)
  G2 3 (7.7%)
  G3 1 (2.6%)
 3 mos post-treatment
  G0 15 (38.5%)
  G1 24 (61.5%)
TABLE 6. Patient-Reported Outcome*
Dysphagia
 Baseline
  G0 13 (100%)
 Maximal
  G0 3 (23.1%)
  G1 4 (30.8%)
  G2 3 (23.1 %)
  G3 3 (23.1 %)
 3 mos post-treatment
  G0 8 (61.5 %)
  G1 1 (7.7 %)
Dyspnea
 Baseline
  G0 8 (61.5 %)
  G1 4 (30.8 %)
  G2 1 (7.7 %)
 Maximal
  G0 8 (61.5 %)
  G1 3 (23.1 %)
  G2 2 (15.4 %)
 3 mos post-treatment
  G0 7 (53.8%)
  G1 5 (38.5%)
  G2 1 (7.7%)
Cough
 Baseline
  G0 3 (23.1%)
  G1 9 (69.2%)
  G2 1 (7.7%)
 Maximal
  G0 3 (23.1%)
  G1 8 (61.5%)
  G2 2 (15.4%)
 3 mos post-treatment
  G0 4 (30.8%)
  G1 9 (69.2%)
Health status versus baseline
 3 mos post-treatment
  Same 6 (46.2%)
  Better 4 (30.8%)
  Worse 2 (15.4%)
  Missing 1 (7.7%)
 6 mos post-treatment
  Same 5 (38.5%)
  Better 3 (23.1%)
  Worse 4 (30.8%)
  Missing 1 (7.7%)
Mobility
 Baseline
  Minor problems 5 (38.5%)
  No problems 7 (53.8%)
  Missing 1 (7.7%)
(Continued)
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Because of these uncertainties, we started a prospective 
single-arm phase II trial in 2006 for patients with synchronous 
oligometastases from NSCLC. Although three quarters of the 
patients had local stage III disease, the 2- and 3-year OS was 
23.3% and 17.5%, respectively. Even more important, both 
the 2- and 3-year PFS was 13.6%. Although a straightforward 
comparison with patients with stage IV NSCLC treated with 
chemotherapy only is not allowed, these results compare well 
with the latter group, in which a median PFS of typically 4 
months is described.35
The present study has shortcomings. Because it was a 
nonrandomized trial, the real possible benefit of radical local 
therapy over chemotherapy alone remains uncertain although 
TABLE 6. (Continued)
Mobility
 3 mos post-treatment
  Important problems 1 (7.7%)
  Minor problems 4 (30.8%)
  No problems 7 (53.8%)
  Missing 1 (7.7%)
 6 mos post-treatment
  Important problems 1 (7.7%)
  Minor problems 4 (30.8%)
  No problems 6 (46.2%)
  Missing 2 (15.4%)
Self-care
 Baseline
  Minor problems 4 (30.8%)
  No problems 8 (61.5%)
  Missing 1 (7.7%)
 3 mos post-treatment
  Severe problems 1 (7.7%)
  Minor problems 3 (23.1%)
  No problems 8 (61.5%)
  Missing 1 (7.7%)
 6 mos post-treatment
  Severe problems 1 (7.7%)
  Minor problems 3 (23.1%)
  No problems 8 (61.5%)
  Missing 1 (7.7%)
Activities of daily living
 Baseline
  Minor problems 5 (38.5%)
  No problems 7 (53.8%)
  Missing 1 (7.7%)
 3 mos post-treatment
  Severe problems 1 (7.7%)
  Minor problems 4 (30.8%)
  No problems 7 (53.8%)
  Missing 1 (7.7%)
 6 mos post-treatment
  Severe problems 1 (7.7%)
  Minor problems 4 (30.8%)
  No problems 7 (53.8%)
  Missing 1 (7.7%)
Mood (fear and uncertainty)
 Baseline
  Minor problems 1 (7.7%)
  No problems 8 (61.5%)
  Missing 4 (30.8%)
 3 mos post-treatment
  Minor problems 1 (7.7%)
  No problems 9 (69.2%)
  Missing 3 (23.1%)
 6 mos post-treatment
  Minor problems 1 (7.7%)
  No problems 8 (61.5%)
  Missing 4 (30.8%)
*Most recent 13 patients, all treated with concurrent chemoradiotherapy.
TABLE 7. Second-Line Treatment after Recurrence
Radical treatment
 Resection left ovary (solitary recurrence) 1 (3%)
 SRS for solitary brain recurrence 4 (12.1%)
Palliative treatment
 No anticancer treatment 9 (27.3%)
 Chemotherapy only 7 (21.2%)
 Erlotinib 1 (3%)
Palliative radiotherapy only
 Bone metastases 2 (6.1%)
 Palliative radiotherapy to bone and chemotherapy 1 (3%)
 WBRT only 1 (3%)
 WBRT and chemotherapy 6 (18.2%)
 SRS and chemotherapy 1 (3%)
SRS, stereotactic radiosurgery; WBRT, whole-brain radiotherapy.
TABLE 8. Variables Associated with Overall Survival and 
Progression-Free Survival
p
Parameter Overall Survival
Progression-Free 
Survival
Volume primary tumor 0.67 0.26
Volume nodes 0.14 0.42
Volume metastases 0.09 0.80
Total tumor volume 0.80 0.49
SUVmax primary tumor 0.99 0.79
SUVmax non brain metastases 0.78 0.95
Local stage 0.37 0.84
WHO performance status 0.93 0.49
Comorbidity score 0.49 0.92
Location metastases 0.52 0.51
Number metastases 0.44 0.60
Histological subtype 0.33 0.75
Sex 0.72 0.73
Age 0.37 0.72
Sequential versus concurrent 0.79 0.18
Chemoradiotherapy — —
SUVmax, mean maximal standardized uptake value; WHO, World Health Organi-
zation. 
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the observation that six of 39 (15%) patients in our study did 
not show disease progression after 2 years is suggestive that 
a subgroup of these patients may be cured or enjoy a long- 
lasting PFS. The acute toxicity was as expected with these 
treatments,28,29 but fortunately long-term side effects were 
rarely observed and not severe, even in the subgroup of 
patients with self-reported toxicity scores. This is in line with 
previous reports on chemoradiotherapy on the quality of life 
of lung cancer patients.36
Another caveat of the study is the obvious patient selec-
tion. Before embarking on this trial, we investigated the inci-
dence of oligometastases in our referral region, covering 853 
553 inhabitants on January 1, 2006. From the 450 newly diag-
nosed patients with lung cancer, about 50% had stage IV dis-
ease at diagnosis and 25 patients with NSCLC per year would 
have been eligible for our trial (data not shown). Nineteen of 
these 25 patients had local stage III NSCLC. In the 4 years’ 
accrual period of this subsequent study, only 39 patients were 
enrolled, compared with the 100 who would theoretically be 
eligible. The included patients were much younger and in a 
better general condition with fewer comorbidities than the 
average NSCLC patient in our region.37 The majority were 
women, which is also discordant with the population average 
with a preponderance of men.37 Moreover, nearly all patients 
(34 of 39) had only one distant metastasis although according 
to the inclusion criteria up to four metastases could have been 
included. In some favorable subgroups of patients with brain 
metastases, long-term survival may indeed be achieved.38,39
Nevertheless, to the best of our knowledge this is the 
first prospective trial on NSCLC patients with synchronous 
distant metastases treated radically, and it does show a small 
but significant group of long-term survivors. Hasselle et al.14 
reported on a group of NSCLC patients that was more hetero-
geneous than ours because the possibility for hypofractionated 
radiotherapy was an inclusion criterion and both synchronous 
and metachronous metastases were allowed, like in the study 
of Cheruvu et al.16 Our series come close to the inclusion 
criteria of Khan et al.,5 although their series was retrospective. 
These differences may account for the diverging OS and PFS 
rates, but all support long-term PFS and OS.
The first site of progression is only in 5% of the patients 
in the high-dose radiotherapy volume or in radically resected 
sites. Most patients recur at distant sites. However, the brain 
represents a special case because nine of 17 patients with 
brain metastases had a cerebral recurrence at sites remote 
from the SRS field. Although randomized studies did not 
show a survival benefit of prophylactic WBRT after SRS over 
SRS alone,32,40 WBRT may be worth investigating in selected 
subgroups.
We believe that the future is to identify specific genetic 
characteristics that underlie the oligometastastic feature and 
the combination of specific agents with local treatment of 
metastases. A recent example of the former is the identification 
of MiRNA 200c that is involved in the epithelial to mesenchy-
mal transformation.41 For the latter, the rational combination 
of targeted agents with radiotherapy42,43 may well be a unique 
opportunity to eradicate distant metastases not only because 
of inhibition of driving mutations, but at the same time also 
because of the induction of specific antitumor immunity.44 In 
conclusion, radical treatment of NSCLC patients with syn-
chronous oligometastases is associated with long-term PFS.
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